Cargando…

Development and Characterization of Chimeric Anti‐carcinoembryonic Antigen Monoclonal Antibodies and Their Fab Fragments

In an attempt to reduce the immunogenicity of two different murine anti‐carcinoembryonic antigen (CEA) monoclonal antibodies (MAbs), KM10 and A10, we produced recombinant mouse/human chimeric MAbs and the respective Fab fragments carrying the variable regions of the murine MAbs. Chimeric A10 Fab fra...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamigaki, Takashi, Ohyanagi, Harumasa, Yamamoto, Masahiro, Kaneda, Teruo, Goto, Takashi, Ohmura, Takao, Yokoyama, Kazumasa, Saitoh, Yoichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 1994
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5919441/
https://www.ncbi.nlm.nih.gov/pubmed/8188529
http://dx.doi.org/10.1111/j.1349-7006.1994.tb02097.x
_version_ 1783317627218690048
author Kamigaki, Takashi
Ohyanagi, Harumasa
Yamamoto, Masahiro
Kaneda, Teruo
Goto, Takashi
Ohmura, Takao
Yokoyama, Kazumasa
Saitoh, Yoichi
author_facet Kamigaki, Takashi
Ohyanagi, Harumasa
Yamamoto, Masahiro
Kaneda, Teruo
Goto, Takashi
Ohmura, Takao
Yokoyama, Kazumasa
Saitoh, Yoichi
author_sort Kamigaki, Takashi
collection PubMed
description In an attempt to reduce the immunogenicity of two different murine anti‐carcinoembryonic antigen (CEA) monoclonal antibodies (MAbs), KM10 and A10, we produced recombinant mouse/human chimeric MAbs and the respective Fab fragments carrying the variable regions of the murine MAbs. Chimeric A10 Fab fragment was expressed in Escherichia coli, and produced in large quantities in a mini‐jar fermentation system. In competitive binding assays, chimeric MAbs and their Fab fragments showed identical specificity to human CEA epitopes, as compared to the parental MAbs or Fab fragments. Both chimeric Fab fragments exhibited strong immunohistochemical reactivity with various gastrointestinal carcinomas and no reactivity with CEA‐related antigens, such as NCA (nonspecific cross‐reacting antigen) or BGPI (biliary glycoprotein I). Furthermore, chimeric KM10 MAb elicited substantially higher antibody‐dependent cellular cytotoxicity than the murine MAb. Complement‐dependent cytotoxicity in vitro was much weaker with chimeric KM10 MAb. These results indicate that chimeric MAbs or Fab fragments could potentially replace the parental murine antibodies or their Fab fragments in therapy or diagnosis of human gastrointestinal carcinomas.
format Online
Article
Text
id pubmed-5919441
institution National Center for Biotechnology Information
language English
publishDate 1994
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-59194412018-05-11 Development and Characterization of Chimeric Anti‐carcinoembryonic Antigen Monoclonal Antibodies and Their Fab Fragments Kamigaki, Takashi Ohyanagi, Harumasa Yamamoto, Masahiro Kaneda, Teruo Goto, Takashi Ohmura, Takao Yokoyama, Kazumasa Saitoh, Yoichi Jpn J Cancer Res Article In an attempt to reduce the immunogenicity of two different murine anti‐carcinoembryonic antigen (CEA) monoclonal antibodies (MAbs), KM10 and A10, we produced recombinant mouse/human chimeric MAbs and the respective Fab fragments carrying the variable regions of the murine MAbs. Chimeric A10 Fab fragment was expressed in Escherichia coli, and produced in large quantities in a mini‐jar fermentation system. In competitive binding assays, chimeric MAbs and their Fab fragments showed identical specificity to human CEA epitopes, as compared to the parental MAbs or Fab fragments. Both chimeric Fab fragments exhibited strong immunohistochemical reactivity with various gastrointestinal carcinomas and no reactivity with CEA‐related antigens, such as NCA (nonspecific cross‐reacting antigen) or BGPI (biliary glycoprotein I). Furthermore, chimeric KM10 MAb elicited substantially higher antibody‐dependent cellular cytotoxicity than the murine MAb. Complement‐dependent cytotoxicity in vitro was much weaker with chimeric KM10 MAb. These results indicate that chimeric MAbs or Fab fragments could potentially replace the parental murine antibodies or their Fab fragments in therapy or diagnosis of human gastrointestinal carcinomas. Blackwell Publishing Ltd 1994-03 /pmc/articles/PMC5919441/ /pubmed/8188529 http://dx.doi.org/10.1111/j.1349-7006.1994.tb02097.x Text en
spellingShingle Article
Kamigaki, Takashi
Ohyanagi, Harumasa
Yamamoto, Masahiro
Kaneda, Teruo
Goto, Takashi
Ohmura, Takao
Yokoyama, Kazumasa
Saitoh, Yoichi
Development and Characterization of Chimeric Anti‐carcinoembryonic Antigen Monoclonal Antibodies and Their Fab Fragments
title Development and Characterization of Chimeric Anti‐carcinoembryonic Antigen Monoclonal Antibodies and Their Fab Fragments
title_full Development and Characterization of Chimeric Anti‐carcinoembryonic Antigen Monoclonal Antibodies and Their Fab Fragments
title_fullStr Development and Characterization of Chimeric Anti‐carcinoembryonic Antigen Monoclonal Antibodies and Their Fab Fragments
title_full_unstemmed Development and Characterization of Chimeric Anti‐carcinoembryonic Antigen Monoclonal Antibodies and Their Fab Fragments
title_short Development and Characterization of Chimeric Anti‐carcinoembryonic Antigen Monoclonal Antibodies and Their Fab Fragments
title_sort development and characterization of chimeric anti‐carcinoembryonic antigen monoclonal antibodies and their fab fragments
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5919441/
https://www.ncbi.nlm.nih.gov/pubmed/8188529
http://dx.doi.org/10.1111/j.1349-7006.1994.tb02097.x
work_keys_str_mv AT kamigakitakashi developmentandcharacterizationofchimericanticarcinoembryonicantigenmonoclonalantibodiesandtheirfabfragments
AT ohyanagiharumasa developmentandcharacterizationofchimericanticarcinoembryonicantigenmonoclonalantibodiesandtheirfabfragments
AT yamamotomasahiro developmentandcharacterizationofchimericanticarcinoembryonicantigenmonoclonalantibodiesandtheirfabfragments
AT kanedateruo developmentandcharacterizationofchimericanticarcinoembryonicantigenmonoclonalantibodiesandtheirfabfragments
AT gototakashi developmentandcharacterizationofchimericanticarcinoembryonicantigenmonoclonalantibodiesandtheirfabfragments
AT ohmuratakao developmentandcharacterizationofchimericanticarcinoembryonicantigenmonoclonalantibodiesandtheirfabfragments
AT yokoyamakazumasa developmentandcharacterizationofchimericanticarcinoembryonicantigenmonoclonalantibodiesandtheirfabfragments
AT saitohyoichi developmentandcharacterizationofchimericanticarcinoembryonicantigenmonoclonalantibodiesandtheirfabfragments